Press Releases

These press releases are intended as reference information for U.S. investors and journalists. These press releases correspond to each fiscal quarter ended and should not be deemed accurate or current except as of the date of the particular press release.

Athersys, Inc. has no intention of updating any of the information contained in previously issued press releases and specifically disclaims any duty to update such information. Readers are urged to refer to the most recent press release and SEC filings for the most current information
 

All Releases
Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
Mar 14, 2019
Substantial progress over the year, advancing programs and expanding collaboration with HEALIOS K.K . Management to host conference call at 4:30 PM EST today CLEVELAND , March 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2018 and annual 2018
Athersys to Host Year-End 2018 Financial Results Call
Feb 14, 2019
CLEVELAND , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019 , and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)
Jan 23, 2019
Results Confirm Safety Profile and Demonstrate Meaningful Potential Benefits in Mortality, Ventilator-free Days and ICU-free Days CLEVELAND , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today summary results from its exploratory clinical study of the intravenous
Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
Dec 17, 2018
Parties working together on development plan in China CLEVELAND, Ohio , Dec. 17, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development
Athersys Reports Third Quarter 2018 Results
Nov 6, 2018
Management to host conference call at 4:30pm EST today CLEVELAND , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended September 30, 2018 . Highlights of the third quarter of 2018 and recent events include: Completed enrollment
Athersys to Host Third Quarter Financial Results Call
Oct 9, 2018
CLEVELAND, Ohio , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday, November 6th, 2018 , and will host a conference call shortly thereafter at 4:30 p.m.
Athersys to Present at 2018 Cell & Gene Meeting on the Mesa
Sep 24, 2018
CEO invited to provide corporate overview and speak in two workshops focusing on innovative development initiatives in Japan and advanced manufacturing technologies CLEVELAND, Ohio , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today that Gil Van Bokkelen , Chairman
Athersys Reports Second Quarter 2018 Results
Aug 7, 2018

Management to host conference call at 4:30pm EDT today CLEVELAND , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2018 . Highlights of the second quarter of 2018 and recent events include: Announced the

Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy
Aug 3, 2018

Company Appoints Greg Liposky, MBA as Senior Vice President of Commercial Manufacturing CLEVELAND , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced the addition of an experienced manufacturing executive to oversee manufacturing operations and help plan for and lead the

Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke
Jul 31, 2018
Pivotal study has received a Special Protocol Assessment (SPA), Fast Track Designation, and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration ( FDA ) CLEVELAND , July 31, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc.